Charles River Laboratories International (CRL) Current Deferred Revenue (2009 - 2025)

Charles River Laboratories International's Current Deferred Revenue history runs 17 years deep, the most recent figure standing at $210.4 million for Q4 2025.

• In Q4 2025, Current Deferred Revenue fell 15.26% year-over-year to $210.4 million; the TTM figure through Dec 2025 stood at $210.4 million (down 15.26% YoY), while the FY2025 annual figure was $210.4 million, down 15.26% from the prior year.
• Current Deferred Revenue was $210.4 million for Q4 2025 at Charles River Laboratories International, down from $237.7 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $290.0 million in Q4 2022 to a low of $210.4 million in Q4 2025.
• Historically, Current Deferred Revenue has averaged $245.6 million across 5 years, with a median of $249.4 million in 2024.
• The sharpest annual moves came in 2021 and 2025: Current Deferred Revenue soared 35.75% in 2021, then slipped 15.26% in 2025.
• A 5-year view of Current Deferred Revenue shows it stood at $219.7 million in 2021, then surged by 32.0% to $290.0 million in 2022, then fell by 5.86% to $273.0 million in 2023, then fell by 9.04% to $248.3 million in 2024, then retreated by 15.26% to $210.4 million in 2025.
• The last three Current Deferred Revenue figures came in at $210.4 million (Q4 2025), $237.7 million (Q3 2025), and $268.3 million (Q2 2025), per Business Quant data.